

PKA Assay Standard


A PKA standard for use in the determination of Prekallikrein Activator (PKA) in Human Blood Products and Biologicals according to the European and US Pharmacopoeias.

PRODUCT CODE: PW30305

5 x 0.5ml

For Research Use Only

INTRODUCTION



The PKA Assay Standard is calibrated against the 3rd International Standard for PKA¹⁻³ and is intended for use in assays of PKA based on the methods outlined in the European and US Pharmacopoeias.

In the Pharmacopoeia method for PKA assays, a Human PreKallikrein pool is first activated to plasma kallikrein by PreKallikrein activator, (PKA -FXIIa) in the test sample. The kallikrein formed then releases p-nitroaniline (pNA) from a chromogenic kallikrein substrate. The amount of pNA released is measured photometrically at 405 nm and is proportional to the level of PKA present in the preparation.

CONTENTS

PKA Standard ~32 IU/ml (5x 0.5ml)

Reconstitute in 0.5 ml of distilled water, leave to stand at room temperature for 10 minutes and mix by gentle swirling. This gives a batch specific PKA concentration of approximately 32IU/ml.

The standards should be stored at 2-8°C until the batch specific expiry date indicated on the box label.

Once reconstituted the standard can be stored for up to 8 hours at 4°C before use, or at -20°C for 6 months.

Additional reagents required:

- **Chromogenic Kallikrein Substrate**
H-D-Pro-Phe-Arg-pNA.
- **Human Prekallikrein Pool**
(PW30304 PKK Pool, 4 x 2.0 ml, is recommended)
- **PKA Assay buffer**

ASSAY METHOD

Follow the method outlined in either the European or US Pharmacopoeia for assays of Prekallikrein Activator (PKA).

WARNINGS & PRECAUTIONS

- The PKA standard has been prepared from human plasma, which has been tested and found negative for HBsAG, HB core, HIV-1 and 2 and HCV antibodies. However, as with all materials of human origin it should be treated as potentially infectious and handled accordingly.
- Care should be taken when handling the reagents contained in this pack.

LITERATURE

1. Fox B, Regourd E, Rigsby P, Longstaff C, Terao E. Joint Collaborative study for the establishment of the WHO 3rd International Standard for Prekallikrein Activator in albumin. Pharmeur Bio & Sci Notes 2020. In preparation.
2. Longstaff C, Behr-Gross M-E, Daas A, Lackner F. An international collaborative study to replace the 1st international standard for prekallikrein activator. Vox Sanguinis 2005; 88:143-151.
3. Longstaff C, Behr-Gross M-E, Daas A, Lackner F. Collaborative Study to Establish a new Biological Reference Preparation for Prekallikrein Activator. Pharmeuropa-Bio, 2005-1, 1-11.

ALL REAGENTS SUPPLIED ARE FOR RESEARCH USE ONLY.



Pathway Diagnostics Ltd
Curtis Road, Dorking, RH4 1EJ, UK
Tel: 0044 1306 888777
www.pathwaydiagnostics.com